gemcitabine has been researched along with Cancer of Nasopharynx in 76 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (22.37) | 29.6817 |
| 2010's | 35 (46.05) | 24.3611 |
| 2020's | 24 (31.58) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Chen, Y; He, QM; He, SW; Huang, SY; Li, XM; Li, YQ; Liu, N; Luo, WJ; Ma, J; Yang, XJ; Zhang, Y; Zhao, Y | 1 |
| Chen, QY; Du, CC; Guo, SS; Liu, LT; Liu, T; Mai, HQ; Yang, ZC | 1 |
| Du, C; Hu, C; Jiang, J; Kong, F; Lv, Y; Ni, M; Ying, H; Zhai, R | 1 |
| Chen, Q; Li, S | 1 |
| Chen, L; Jiang, N; Li, JY; Li, WF; Li, XM; Li, YQ; Liu, N; Ma, J; Mao, YP; Tang, LL; Zhang, XM; Zhang, Y; Zhou, GQ | 1 |
| Cai, MB; Li, ZM; Nie, YH; Tan, YR; Yang, Q; Zhu, HB | 1 |
| An, HJ; Cho, S; Hong, MH; Jung, HA; Keam, B; Lee, KW; Lim, J; Ock, CY; Park, KU; Park, WY; Pereira, S; Yun, T | 1 |
| Chen, MY; Ding, X; Duan, CY; Gu, CM; Hua, YJ; Huang, PY; Liu, YL; Liu, YP; Ouyang, YF; Wang, X; Wang, ZQ; Xu, HS; You, R; Zhang, MX; Zhang, WJ; Zou, X | 1 |
| Chen, Q; Li, S; Shen, L | 1 |
| Chen, YP; Guan, JL; Guo, R; He, QM; He, SW; Huang, ZL; Jin, X; Kuang, DM; Li, GB; Li, JY; Li, WF; Li, XM; Liang, XY; Liu, N; Lv, J; Ma, J; Mao, YP; Shen, JY; Sun, R; Sun, Y; Tang, LL; Wang, SQ; Wei, C; Wei, Y; Xiong, KX; Yin, JH; Zhang, CJ; Zhang, Y; Zheng, YH; Zhou, GQ; Zhou, WW | 1 |
| Chen, D; Chen, QY; Chen, X; Chen, Y; Feng, H; He, X; Hsieh, CY; Hu, C; Jiang, Y; Jin, F; Jing, S; Keegan, P; Li, J; Li, P; Li, Q; Liao, W; Lim, WT; Lin, X; Liu, YC; Lu, Y; Luo, X; Mai, HQ; Pan, J; Qu, S; Samol, J; Shi, Y; Tang, X; Wang, HM; Wang, S; Wang, X; Wen, J; Xu, R; Xu, RH; Yang, K; Yang, MH; Yao, S; Yen, CJ; Yuan, X | 1 |
| Ai, P; Chen, N; Duan, B; Li, Y; Shi, H; Tian, J; Zhu, J | 1 |
| Jin, C; Wen, F; Xu, T; Zhan, M; Zheng, H | 1 |
| Li, G; Li, H; Peng, C; Shi, L; Zhou, C | 1 |
| Cabezas-Camarero, S; Cabrera-Martín, MN; Pérez-Alfayate, R; Pérez-Segura, P; Puebla, F | 1 |
| Li, C; Luo, S; Shi, M; Wang, J; Xu, M; Zang, J; Zhao, L | 1 |
| Luttke, M; Marschner, S; Späth, R; Walter, F | 1 |
| Chen, WP; Huang, YM; Li, SL; Lu, L; Qi, CH; Qiao, SQ | 1 |
| Chen, HB; Chen, SW; Fei, Q; He, X; Xu, JJ; Zhang, CM | 1 |
| Liu, D; Liu, X; Qiu, R; Zhang, W | 1 |
| Cui, J; Pan, LX; Tan, HF; Xiao, Z; Zhang, LL | 1 |
| Jia, Z; Tang, M; Zhang, J | 1 |
| Cao, JX; Lu, FT; Luo, F; Luo, M; Luo, QY; Ma, WJ; Pan, WT; Qiu, MZ; Xia, ZF; Yang, DJ; Zeng, KM; Zhang, L; Zhang, ZH; Zhao, HY; Zhou, T | 1 |
| Abdallah, IB; Balti, M; Chourabi, C; Fehri, W; Haddaoui, A; Nasr, SB; Zribi, A | 1 |
| Kang, W; Li, Y; Liao, J; Xiao, L | 1 |
| Fong, KW; Hussain, A; Ong, WS; Sommat, K; Soong, YL; Tan, T; Wee, J | 1 |
| de Greeuw, I; Eersels, JLH; Greijer, AE; Middeldorp, JM; Molthoff, CFM; Novalić, Z; Verkuijlen, SAWM; Verlaan, M | 1 |
| He, X; Hu, C; Ou, D; Wu, M | 1 |
| Hu, C; Li, Y; Lu, X; Qian, W; Xu, T | 1 |
| Kwong, DLW | 1 |
| Li, B; Liao, W; Wen, H; Xu, P; Zhang, S; Zheng, L | 1 |
| Brunner, TB; Willich, C | 1 |
| Fan, JF; Jiang, W; Kong, XY; Liao, SF; Lu, JX; Mi, JL; Qin, XL; Tang, HY; Xu, QL; Yao, DC; Yu, XW; Zhang, J; Zhang, RJ | 1 |
| Chen, X; Jiang, J; Liang, W; Wan, N; Yang, Y; Zhang, L; Zhang, T | 1 |
| Sidaway, P | 1 |
| Chen, MY; Guo, L; Hong, MH; Huang, HQ; Jiang, R; Liu, Q; Mai, HQ; Qian, CN; Qiu, F; Sun, R; Xia, ZJ; Zhang, L; Zou, X | 1 |
| Hussain, R; Iqbal, H; Jamshed, A | 1 |
| Chen, XZ; Jin, T; Li, B | 1 |
| Ang, MK; Cheah, SL; Fong, KW; Lim, WT; Ng, QS; Ong, WS; Quah, D; Soo, KC; Soong, YL; Tan, D; Tan, SH; Tan, T; Wee, J; Yip, C | 1 |
| de Boer, JP; Greijer, AE; Huitema, AD; Juwana, H; Middeldorp, JM; Novalić, Z; Stoker, SD; Tan, IB; Verkuijlen, SA; Wildeman, MA | 1 |
| Huang, CB; Huang, LL; Lin, SJ; Pan, JJ; Qiu, SF; Xu, YJ; Zheng, W; Zong, JF | 1 |
| Chang, YF; Chen, SY; Hsiao, CH; Hsieh, JC; Hsieh, RK; Hsu, CL; Lee, KD; Lu, CH; Ng, SH; Shiau, CY; Wang, CH; Wang, HM; Yeh, KH | 1 |
| Gu, MF; Li, JJ; Li, Y; Li, YQ; Liu, LZ; Pan, K; Shen, WX; Xia, JC; Zhang, H | 1 |
| Barreca, GS; Costa, C; Donato, G; Focà, A; Giancotti, A; La Boria, A; Liberto, MC; Pisani, V; Roveda, L; Strazzulla, A; Torti, C; Tucci, L; Zicca, E | 1 |
| Chang, KP; Chang, YS; Fan, HC; Hsieh, CH; Hsu, CL; Huang, Y; Huang, YC; Kuo, YC; Lee, LY; Li, HP; Lin, AC; Lin, TL; Lui, KW; Wang, HM | 1 |
| Dong, M; Gui, L; He, X; Hu, S; Jia, B; Liu, P; Qin, Y; Yang, J; Yang, S; Zhang, C; Zhou, S | 1 |
| Fang, W; Tian, Y; Xue, C; Zhan, J; Zhang, J; Zhang, L; Zhao, Y | 1 |
| Cheah, SL; Chua, ML; Fong, KW; Kusumawidjaja, G; Shwe, MT; Soong, YL; Tan, SH; Tan, TW; Wee, JT | 1 |
| Hong, S; Zhang, L | 1 |
| Jiang, W; Luo, S; Pan, H; Shi, M; Wang, J; Xu, M; Zang, J; Zhao, L; Zhou, Y | 1 |
| Feng, B; Fu, JT; Hu, Y; Shi, D; Shi, Z | 1 |
| Hee, SW; Leong, SS; Lim, WT; Poon, D; Rajan, S; Tan, EH; Tay, MH; Toh, CK; Wee, J | 1 |
| Bharadwaj, RR; Chen, EX; Jarvi, A; Kamel-Reid, S; Le Tourneau, C; Mann, V; Perez-Ordonez, B; Siu, LL; Wang, L; You, B | 1 |
| He, X; Hu, C; Liu, T; Ou, D; Xiayun, H; Ying, H; Zhu, G | 1 |
| Gu, MF; He, LJ; Li, JJ; Liu, LZ; Luo, GY; Xu, GL; Yan, CX; Yuan, WX; Zhang, HM; Zhang, R | 1 |
| Cai, XY; Cai, YC; Cao, Y; Hu, WH; Jiang, WQ; Jin, Y; Shi, YX; Xia, XY; Zhang, WD | 1 |
| Hu, ZH; Huang, Y; Xue, C; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY | 1 |
| An, X; Chen, C; Chen, YC; Li, YH; Luo, HY; Wang, FH; Wang, ZQ; Xu, RH; Zhang, L | 1 |
| de Boer, JP; Greijer, AE; Huitema, AD; Juwana, H; Middeldorp, JM; Novalic, Z; Tan, IB; Verkuijlen, SA; Wildeman, MA | 1 |
| Chua, M; Coleman, A; Collins, M; Corry, J; D'Costa, I; Hicks, RJ; Lim, AM; Peters, L; Rischin, D; Solomon, B | 1 |
| Machin, D; Tan, SB | 1 |
| Au, SK; Chan, TM; Cheung, FY; Chiu, CY; Foo, W; Kwok, CH; Lau, WH; Law, CK; Ngan, RK; Tse, KC; Yau, S; Yiu, HH | 1 |
| Edmonds, MR; Ma, BB; Pond, GR; Siu, LL; Tannock, IF | 1 |
| Foo, KF; Leong, SS; Lim, WT; Tan, EH; Tan, SB; Tan, T; Tay, MH; Thng, CH; Toh, CK; Wee, J | 1 |
| He, QM; Huang, MJ; Jiang, Y; Liu, JY; Luo, F; Peng, F; Wei, YQ; Zou, LQ | 1 |
| Au, GK; Chua, DT; Sham, JS | 1 |
| Brown, S; Chen, EX; Chin, SF; Duran, I; Nottage, M; Oza, AM; Pond, GR; Siu, LL; Sturgeon, J | 1 |
| Chang, JY; Hong, RL; Lin, CY; Liu, TW; Wang, CC; Yu, YC | 1 |
| Guo, Y; Hong, XN; Li, J; Tang, WY; Wang, JL | 1 |
| Chan, EW; Lee, AW; Ng, WT; Soong, IS; Tong, M; Wong, DH; Yau, TK; Yeung, RM | 1 |
| Lee, AW; Ng, WT; Pang, ES; Soong, IS; Wong, DH; Yau, TK; Yeung, RM | 1 |
| Cheng, WW; Cho, WC; Law, SC; Ma, VW; Ngan, RK; Podust, VN; Yip, C; Yip, TT; Yip, V; Yiu, HH | 1 |
| Gu, Y; Guo, Y; Hong, X; Hu, X; Li, J; Tang, W; Wang, B; Wang, J | 1 |
| Guan, ZZ; Huang, PY; Peng, PJ; Xu, F; Zhang, L; Zhang, Y | 1 |
| Fong, KW; Foo, KF; Koh, L; Leong, SS; Lian, LG; Machin, D; Tai, BC; Tan, EH; Tan, T; Wee, JT | 1 |
| Foo, KF; Machin, D; Tai, BC; Tan, EH; Tan, SB | 1 |
5 review(s) available for gemcitabine and Cancer of Nasopharynx
| Article | Year |
|---|---|
The efficacy and safety of gemcitabine-based induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Case-Control Studies; Chemoradiotherapy; China; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Observational Studies as Topic; Progression-Free Survival; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2021 |
The safety and efficacy of gemcitabine and cisplatin (GP)-based induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2022 |
Gemcitabine-Related Atrial Fibrillation: A Case Report and Review of the Literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Nasopharyngeal Neoplasms | 2022 |
A meta-analysis comparing the efficacy and safety of gemcitabine plus cisplatin induction chemotherapy in patients with locoregionally advanced NPC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2022 |
Nasopharyngeal carcinoma: review of the literature with a focus on therapeutical implications.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Evidence-Based Medicine; Gemcitabine; Humans; Immunotherapy, Adoptive; Lymphocyte Activation; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Treatment Outcome; Valproic Acid | 2015 |
27 trial(s) available for gemcitabine and Cancer of Nasopharynx
| Article | Year |
|---|---|
A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11).
Topics: Antineoplastic Combined Chemotherapy Protocols; Artificial Intelligence; B7-H1 Antigen; Chromatin; Deoxycytidine; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Nivolumab; Programmed Cell Death 1 Receptor | 2022 |
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cisplatin; Double-Blind Method; Female; Gemcitabine; Humans; Internationality; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; United States | 2023 |
Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in the first-line setting for Chinese patients with metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Markov Chains; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Quality-Adjusted Life Years | 2020 |
Efficacy and safety of two different adjuvant chemotherapy regimens in combination with concurrent chemoradiotherapy in treating patients with advanced nasopharyngeal carcinoma: A protocol for randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Multicenter Studies as Topic; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Progression-Free Survival; Radiotherapy, Intensity-Modulated; Randomized Controlled Trials as Topic | 2021 |
Thyroid V40 Predicts Primary Hypothyroidism After Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Hypothyroidism; Incidence; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Pituitary Gland; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Regression Analysis; Thyroid Gland; Time Factors | 2017 |
Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Compliance; Progression-Free Survival; Radiotherapy, Intensity-Modulated; Young Adult | 2017 |
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as a first-line concurrent chemotherapy regimen in nasopharyngeal carcinoma: a prospective, multi-institution, randomized controlled phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Prospective Studies; Young Adult | 2019 |
A phase II trial of Endostar combined with gemcitabine and cisplatin chemotherapy in patients with metastatic nasopharyngeal carcinoma (NCT01612286).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Endostatins; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Recombinant Proteins; Treatment Outcome | 2013 |
Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Patient Compliance; Quality of Life; Radiation-Sensitizing Agents | 2015 |
Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.
Topics: Adult; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; DNA, Viral; Female; Gemcitabine; Herpesvirus 4, Human; Humans; Immunoglobulin A; Immunoglobulin G; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; T-Lymphocytes; Valproic Acid; Virus Latency | 2015 |
Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial.
Topics: Adult; Aged; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Prospective Studies; Survival Analysis; Taiwan; Treatment Outcome | 2015 |
Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Protocols; Carcinoma; Cisplatin; Cytokine-Induced Killer Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis | 2015 |
Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate | 2016 |
A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
Experience with combination of cisplatin plus gemcitabine chemotherapy and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Chemotherapy, Adjuvant; China; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Treatment Outcome | 2012 |
Sequential chemoradiotherapy with gemcitabine and cisplatin for locoregionally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Cisplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Treatment Outcome; Young Adult | 2013 |
Salvage gemcitabine-vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Risk Factors; Salvage Therapy; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lymphatic Metastasis; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Radiotherapy, Intensity-Modulated; Remission Induction; Ribonucleotide Reductases; Survival Rate; Young Adult | 2013 |
Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome | 2002 |
Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neutropenia; Paclitaxel; Severity of Illness Index; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2005 |
Gemcitabine and cisplatin in advanced nasopharyngeal carcinoma: a pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Nasopharyngeal Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Endometrial Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasms; Ovarian Neoplasms | 2006 |
Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Treatment of Stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: impact of chemotherapy schemes.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Radiotherapy, Conformal; Survival Analysis; Survival Rate; Treatment Outcome | 2006 |
Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Platinum Compounds; Survival Rate; Treatment Outcome | 2008 |
Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type.
Topics: Adult; Aged; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Survival Rate; Time Factors | 2002 |
A Bayesian re-assessment of two Phase II trials of gemcitabine in metastatic nasopharyngeal cancer.
Topics: Antimetabolites, Antineoplastic; Bayes Theorem; Deoxycytidine; Gemcitabine; Humans; Nasopharyngeal Neoplasms; Neoplasm Metastasis | 2002 |
44 other study(ies) available for gemcitabine and Cancer of Nasopharynx
| Article | Year |
|---|---|
Gemcitabine synergizes with cisplatin to inhibit nasopharyngeal carcinoma cell proliferation and tumor growth.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Management of first-line palliative chemotherapy for post-treatment metastasis after gemcitabine plus cisplatin induction chemotherapy: Gemcitabine plus cisplatin and non-gemcitabine plus cisplatin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2022 |
Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis.
Topics: Carcinoma; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids; Treatment Outcome | 2022 |
Gemcitabine Versus Docetaxel Plus Cisplatin as Induction Chemotherapy in Nasopharyngeal Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Retrospective Studies | 2022 |
The immune modulation effects of gemcitabine plus cisplatin induction chemotherapy in nasopharyngeal carcinoma.
Topics: Cisplatin; Deoxycytidine; Gemcitabine; HLA-DR Antigens; Humans; Induction Chemotherapy; Interleukin-2; Interleukin-5; Interleukin-6; Interleukin-8; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2022 |
Gemcitabine Combined with Cisplatin Has a Better Effect in the Treatment of Recurrent/Metastatic Advanced Nasopharyngeal Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Quality of Life; Retrospective Studies; Treatment Outcome | 2022 |
Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Circulating Tumor DNA; Clinical Trials as Topic; Deoxycytidine; Endothelial Growth Factors; Gemcitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Necrosis; Neoplasm Recurrence, Local; Pyridines | 2022 |
Tumor volume reduction after induction chemotherapy with gemcitabine plus cisplatin in nasopharyngeal carcinoma.
Topics: Cisplatin; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Retrospective Studies; Tumor Burden | 2023 |
The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Tumor Microenvironment | 2023 |
Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2019 |
Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis.
Topics: Adult; Aged; Angiography, Digital Subtraction; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Floxuridine; Follow-Up Studies; Gemcitabine; Hepatic Artery; Humans; Infusion Pumps; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Retrospective Studies; Treatment Outcome; Vascular Access Devices | 2020 |
Increased clinical and plasma EBV DNA responses to platinum-gemcitabine after nivolumab in patients with heavily platinum-pretreated nasopharyngeal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; DNA, Viral; Epstein-Barr Virus Infections; Gemcitabine; Herpesvirus 4, Human; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Nivolumab; Organoplatinum Compounds | 2020 |
Gemcitabine and cisplatin versus docetaxel and cisplatin as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma from non-endemic area of China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; China; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Treatment Outcome | 2020 |
[Induction Chemotherapy with Gemcitabine and Cisplatin followed by Radiochemotherapy in locally advanced Nasopharyngeal Carcinoma].
Topics: Chemoradiotherapy; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2020 |
Gemcitabine combined with cisplatin vs. taxane, cisplatin, and fluorouracil in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective case-control study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Retrospective Studies; Taxoids; Time Factors | 2020 |
Precise engineering of hybrid molecules-loaded macromolecular nanoparticles shows
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Chemistry, Pharmaceutical; Cisplatin; Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; Nasopharyngeal Neoplasms; Polylactic Acid-Polyglycolic Acid Copolymer; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; bcl-X Protein; Caspases; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Janus Kinase 2; Models, Biological; Myeloid Cell Leukemia Sequence 1 Protein; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Piperidines; Signal Transduction; Small Molecule Libraries; STAT3 Transcription Factor | 2021 |
Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model.
Topics: Animals; Antiviral Agents; Carcinoma; Deoxycytidine; Disease Models, Animal; DNA, Viral; Epstein-Barr Virus Infections; Ganciclovir; Gemcitabine; Herpesvirus 4, Human; Humans; Mice; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Treatment Outcome; Tumor Cells, Cultured; Valproic Acid; Viral Load; Virus Activation | 2017 |
Radiation-induced nasopharyngeal ulcers after intensity modulated radiotherapy in primary nasopharyngeal carcinoma patients: A dose-volume-outcome analysis.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Radiation; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Diseases; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Radiation Injuries; Radiotherapy Dosage; Radiotherapy, High-Energy; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Outcome; Ulcer | 2018 |
Camrelizumab for nasopharyngeal carcinoma: a new hope?
Topics: Carcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2018 |
Tumor Volume Reduction After Gemcitabine Plus Cisplatin Induction Chemotherapy in Locally Advanced Nasopharyngeal Cancer: Comparison with Paclitaxel and Cisplatin Regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; China; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis; Tumor Burden | 2018 |
[Adjuvant chemotherapy with cisplatin and gemcitabine after radiochemotherapy with curative intent does not improve relapse-free survival in nasopharyngeal cancer patients with persistently detectable EBV DNA].
Topics: Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; DNA; Gemcitabine; Herpesvirus 4, Human; Humans; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local | 2019 |
Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Health Care Costs; Humans; Male; Markov Chains; Multicenter Studies as Topic; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic | 2019 |
Induction chemotherapy improves efficacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2019 |
Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Paclitaxel; Palliative Care; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Gemcitabine and Cisplatin followed by chemo-radiation for advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2014 |
Analysis on clinical characteristics and influencing factors of patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Risk Factors | 2015 |
Application of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinoma.
Topics: Animals; Anticonvulsants; Antimetabolites, Antineoplastic; Antiviral Agents; Apoptosis; Carcinoma; Cell Proliferation; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Epstein-Barr Virus Infections; Ganciclovir; Gemcitabine; Gene Expression Profiling; Herpesvirus 4, Human; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Inbred NOD; Mice, SCID; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Oncolytic Virotherapy; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Valproic Acid; Viral Load; Virus Activation; Xenograft Model Antitumor Assays | 2015 |
[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy].
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Ifosfamide; Induction Chemotherapy; Kaplan-Meier Estimate; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neutropenia; Platinum; Remission Induction; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Failure | 2015 |
In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms, Experimental; Quinazolines; Structure-Activity Relationship | 2016 |
Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: A pooled analysis of two randomised controlled trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA, Viral; Epstein-Barr Virus Infections; Female; Fluorouracil; Gemcitabine; Herpesvirus 4, Human; Humans; Leukocyte Count; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Neutrophils; Prognosis; Proportional Hazards Models; Radiotherapy; Randomized Controlled Trials as Topic; Singapore; Survival Rate | 2016 |
Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2017 |
Clinical efficacy and safety of gemcitabine plus nedaplatin in the treatment of advanced nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Case-Control Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Treatment Outcome | 2016 |
Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Prognosis; Quality of Life; Survival Rate | 2008 |
Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Retrospective Studies | 2012 |
Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Remission Induction; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins | 2012 |
Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors.
Topics: Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Female; Gemcitabine; Herpesvirus 4, Human; Humans; Immunoglobulin G; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Treatment Outcome; Valproic Acid; Viral Load; Virus Activation | 2012 |
Bayesian two-stage designs for phase II clinical trials.
Topics: Antimetabolites, Antineoplastic; Bayes Theorem; Carcinoma; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Nasopharyngeal Neoplasms; Sample Size; Singapore | 2002 |
Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome | 2002 |
Induction chemotherapy with cisplatin and gemcitabine followed by reirradiation for locally recurrent nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Survival Rate | 2005 |
[Experience of gemcitabine plus cisplatin chemotherapy in 52 patients with head and neck cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis | 2005 |
Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Quality of Life; Radiotherapy Dosage; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2006 |
ProteinChip array profiling for identification of disease- and chemotherapy-associated biomarkers of nasopharyngeal carcinoma.
Topics: Adult; Alpha-Globulins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Platelet Factor 4; Protein Array Analysis; Protein Precursors; Salvage Therapy | 2007 |
Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |